TrialReader


Avanafil Versus Sildenafil in Spinal Cord Injury Erectile Dysfunction

NCT03169582 — Phase 4, Unknown, 78 participants, Eduardo Vargas-Baquero

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

Avanafil Versus Sildenafil in Spinal Cord Injury Erectile Dysfunction: Non- Inferiority, Randomized, Crossover, Open Clinical Trial

RegistryNCT03169582
StatusUnknown
PhasePhase 4
Study typeInterventional; randomized, crossover, masking: none, treatment
Enrollment78 (Estimated)
SponsorEduardo Vargas-Baquero (Other)
ConditionsErectile Dysfunction
InterventionsAvanafil, Sildenafil (Drug)
Datesstart 2016-04-01, primary completion 2018-06-01 (estimated), completion 2018-06-01 (estimated), first posted 2017-05-30, last updated 2017-05-30
Locations1 site in Spain

Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Erectile Dysfunction All trials of Avanafil All trials of Sildenafil

-Summary

The main goal of this study is to compare the use of Avanafil versus Sildenafil in spinal cord injury erectile dysfunction. The study has the characteristics of a non- inferiority, randomized, crossover, open clinical trial. The principal variable is the IIEF-EF (Erectile Function Domain questionnaire of the International Index of Erectile Function IIEF).

This is an interventional study

Expand all sections  ·  Collapse all

+Arms and interventions

ArmTypeInterventionsDescription
AvanafilActive comparatorDrug: AvanafilClinical evaluation of the two pharmacological interventions (Sildenafil vs Avanafil).
SildenafilActive comparatorDrug: SildenafilClinical evaluation of the two pharmacological interventions (Sildenafil vs Avanafil)
  • Avanafil (Drug), also known as no other interventions: Drug administration (Avanafil)
  • Sildenafil (Drug), also known as no other interventions: Drug administration (Sildenafil)

+Outcome measures

Primary outcomes

  • IIEF-EF [2 years]: Erectile Function Domain questionnaire of the International Index of Erectile Function.

Secondary outcomes

  • SLQQ-Part II [2 years]: Sexual life quality Questionnaire
  • GAQ [2 years]: Global Impression of efficacy

+Eligibility

Sex: Male, ages: 18 Years to any

Inclusion Criteria:

* Spinal cord injury
* Erectile dysfunction
* No Medical Contraindication to use Avanafil and/or Sildenafil
* Able to provide informed consent
* Able to complete questionnaires

Exclusion Criteria:

* Medical Contraindication to use Avanafil and/or Sildenafil
* No spinal cord injury
* Congenital spinal cord injury
* Not able to provide informed consent
* Not able to complete questionnaires

+Locations (1)

FacilityCityCountryStatus
Hospital Nacional de ParaplejicosToledoSpainRecruiting

My Notes